Acquired Resistance for Immune Checkpoint Inhibitors in Cancer Immunotherapy: Challenges and Prospects

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2022 Jan 17

PMID 35037899

Authors

Xunrui Chen

Wenhui Zhang

Wenyan Yang

Min Zhou

Feng Liu

Affiliations

Soon will be listed here.

Abstract

Drug resistance has become an obstacle to the further development of immunotherapy in clinical applications and experimental studies. In the current review, the acquired resistance to immunotherapy was examined. The mechanisms of acquired resistance were based on three aspects as follows: The change of the tumor functions, the upregulated expression of inhibitory immune checkpoint proteins, and the effects of the tumor microenvironment. The combined use of immunotherapy and other therapies is performed to delay acquired resistance. A comprehensive understanding of acquired drug resistance may provide ideas for solving this dilemma.

Citing Articles

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.

Almawash S Cancers (Basel). 2025; 17(5).

PMID: 40075727 PMC: 11899125. DOI: 10.3390/cancers17050880.

Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade.

Li Z, Liu S, Liu D, Yang K, Xiong J, Fang Z J Exp Clin Cancer Res. 2025; 44(1):84.

PMID: 40038799 PMC: 11881293. DOI: 10.1186/s13046-025-03318-6.

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine.

Dinic J, Jovanovic Stojanov S, Dragoj M, Grozdanic M, Podolski-Renic A, Pesic M Life (Basel). 2024; 14(9).

PMID: 39337925 PMC: 11433531. DOI: 10.3390/life14091142.

Drug resistance and tumor immune microenvironment: An overview of current understandings (Review).

Liu Y, Liang J, Zhang Y, Guo Q Int J Oncol. 2024; 65(4).

PMID: 39219258 PMC: 11387120. DOI: 10.3892/ijo.2024.5684.

References

Brennan C, Garrett W . Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2018; 17(3):156-166. PMC: 6589823. DOI: 10.1038/s41579-018-0129-6. View

Zou R, Wang Y, Ye F, Zhang X, Wang M, Cui S . Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. Clin Transl Oncol. 2021; 23(11):2237-2252. DOI: 10.1007/s12094-021-02637-2. View

Andrews L, Yano H, Vignali D . Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019; 20(11):1425-1434. DOI: 10.1038/s41590-019-0512-0. View

Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean M, Validire P, Trautmann A . Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest. 2012; 122(3):899-910. PMC: 3287213. DOI: 10.1172/JCI45817. View

Anagnostou V, Smith K, Forde P, Niknafs N, Bhattacharya R, White J . Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov. 2016; 7(3):264-276. PMC: 5733805. DOI: 10.1158/2159-8290.CD-16-0828. View

Konen J, Rodriguez B, Fradette J, Gibson L, Davis D, Minelli R . Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. Cancers (Basel). 2019; 11(4). PMC: 6521201. DOI: 10.3390/cancers11040462. View

Vetizou M, Pitt J, Daillere R, Lepage P, Waldschmitt N, Flament C . Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350(6264):1079-84. PMC: 4721659. DOI: 10.1126/science.aad1329. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

10.

Tran L, Theodorescu D . Determinants of Resistance to Checkpoint Inhibitors. Int J Mol Sci. 2020; 21(5). PMC: 7084564. DOI: 10.3390/ijms21051594. View

11.

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

12.

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

13.

Zhao X, Subramanian S . Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy. Cancer Res. 2017; 77(4):817-822. DOI: 10.1158/0008-5472.CAN-16-2379. View

14.

Arenas-Ramirez N, Sahin D, Boyman O . Epigenetic mechanisms of tumor resistance to immunotherapy. Cell Mol Life Sci. 2018; 75(22):4163-4176. PMC: 11105392. DOI: 10.1007/s00018-018-2908-7. View

15.

Sahin U, Tureci O . Personalized vaccines for cancer immunotherapy. Science. 2018; 359(6382):1355-1360. DOI: 10.1126/science.aar7112. View

16.

Goodman A, Castro A, Pyke R, Okamura R, Kato S, Riviere P . MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 2020; 12(1):45. PMC: 7236948. DOI: 10.1186/s13073-020-00743-4. View

17.

Limagne E, Richard C, Thibaudin M, Fumet J, Truntzer C, Lagrange A . Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology. 2019; 8(4):e1564505. PMC: 6422400. DOI: 10.1080/2162402X.2018.1564505. View

18.

Vetizou M, Trinchieri G . Anti-PD1 in the wonder-gut-land. Cell Res. 2018; 28(3):263-264. PMC: 5835771. DOI: 10.1038/cr.2018.12. View

19.

Ariyan C, Brady M, Siegelbaum R, Hu J, Bello D, Rand J . Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunol Res. 2018; 6(2):189-200. PMC: 6857638. DOI: 10.1158/2326-6066.CIR-17-0356. View

20.

Darragh L, Oweida A, Karam S . Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment. Front Immunol. 2019; 9:3154. PMC: 6366147. DOI: 10.3389/fimmu.2018.03154. View